◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › BOLD

Boundless Bio, Inc. (BOLD) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-15

Boundless Bio, Inc. (BOLD) operates in the Biotechnology industry and is headquartered in San Diego, United States with about 28 employees. Its market capitalization is roughly $55 million. In the fiscal year ended 2025-12-31, BOLD reported $0M in revenue and ($58M) in net income.

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers.

Interactive charts & full statements →

BOLD Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($64M)($73M)($55M)($46M)
Net Income($58M)($65M)($49M)($46M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BOLD Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Revenue$0M$0M$0M$0M$0M
Operating Income (EBIT)($14M)($14M)($15M)($17M)($17M)
Net Income($14M)($13M)($14M)($16M)($16M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

BOLD Free Cash Flow History

BOLD Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$157M$206M$130M$77M
Total Liabilities$58M$56M$257M$158M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive BOLD viewer.

Other Companies in Biotechnology

← BOKFAll stocksBOLT →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.